rejuvant life tabs

Rejuvenate Bio bags $10m to develop gene therapy for aging

Latest articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...
Rejuvant

San Diego-based start-up raises over $10m in series A funding and will use gene therapy, proprietary targets and the animal health market to commercialise anti-aging therapies.

It’s a dog’s life – but a new therapy could mean it’s a longer, healthier dog’s life. Rejuvenate Bio has announced it has raised over $10 million in a Series A funding round
led by Kendall Capital Partners, a Boston-based firm focused on early-stage biotech companies. Additional investors in-round include gene therapy pioneer Dr Katherine High, V Capital, KdT Ventures and Digitalis Ventures.

Longevity.Technology: Multi-morbidities often require numerous therapies, but what if there was one treatment that could tackle several age-related conditions at once? This is what Harvard start-up Rejuvenate Bio has in mind; the company is working on combination gene therapy to reverse aging in man and man’s best friend and has raised more than $10m to advance its treatment of heart disease in dogs and aging-related conditions in humans, which include heart failure, kidney failure, Type 2 diabetes and obesity.

After first demonstrating its efficacy in treating multiple age-related diseases in mice, the company’s first therapeutic target is the leading type of heart failure in dogs, mitral valve disease (MVD). Certain dog breeds, such as Cavalier King Charles Spaniels, are especially prone to MVD, with more than 80% of animals developing the incurable disease in their lifetime.

Rejuvenate Bio partnered with the American Cavalier King Charles Spaniel Club to launch a preclinical study in dogs with MVD in the autumn of 2019. Results of that study will be used to inform future clinical trials in humans.

Rejuvenate Bio CEO Dan Oliver co-founded the company alongside top geneticist George Church, PhD, and Noah Davidsohn, PhD, a former postdoctoral fellow in Church’s lab at Harvard and the company’s chief scientific officer.

George Church
George Church, Co-Founder and SAB, Rejuvenate Bio

“We are fortunate to double-dip on our data – often, data generated in dogs not only serves as a step forward for animal health, but also as preclinical data for human health products,” said Oliver. “A key experiment outstanding for us is an FDA safety trial if viewed from the animal health lens, which will also serve as a pre-IND toxicity study for human clinical trials [1].”

Elevant

Rejuvenate Bio’s gene therapy increases expression of the genes sTGFβR2 and FGF21 which reduces levels of the cytokine TGF-beta1 and ups levels of the hormone FGF21; both these genes have demonstrated longevity associations.

 


 

“Rarely does an opportunity exist to monetize animal trials while conducting research for human trials and applications.”

 


 

“What we have seen from using a combination of two genes is the ability to affect multiple age-related diseases at once,” Oliver said.

In earlier murine models, using a serotype of adeno-associated virus (AAV8) as the delivery method, reduction in kidney atrophy, improved heart function and a complete reversal of weight gain were observed; in addition, the delivered genes remained separate from the animals’ genomes, meaning they were not passed on to future generations.

Canine model experiments are equally encouraging. “In dogs thus far, we’ve seen the ability to consistently over-express those proteins. We’ve had these treatments in dogs for over a year now and seen no adverse events,” said Oliver, explaining that Rejuvenate Bio expects to publish data from this study later this year.

Ryan Kole, Partner at VCapita, commented: “Rarely does an opportunity exist to monetize animal trials while conducting research for human trials and applications. The combination of talent on this leadership team represents VCapital’s belief that the jockey is as, if not more, important as the horse in analyzing potential for success. We are delighted to work with Daniel Oliver, Dr Davidsohn and Professor Church on their quest to improve both lifespan and health span [2].”

Elevant

[1] https://bit.ly/3nicraC
[2] https://bit.ly/3dOZhir

Image credit: Courtney Mihaka / Unsplash and George Church / Rejuvenate  Bio

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

FOXO exclusively licenses epigenetic clocks from UCLA

FOXO Technologies' exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer. FOXO Technologies Inc has announced the licence of...

Longevity investment: small sums behind big ideas

Sonia Arrison talks about her journey to becoming an early stage investor and what longevity means to her. While longevity is now seeing increasing interest...

ChromaDex and H&H announce Niagen supply agreement

H&H Group expands Swisse healthy aging product line into growing NAD+ space with Niagen from ChromaDex. Los Angeles-based ChromaDex has announced it entered into a strategic...
Supps report ad middle